Glaucoma Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion

Glaucoma Market Report

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Glaucoma Market Growth Potential: How Will Market Size Shift Through 2030?

The glaucoma market size has shown significant expansion in recent years. It is anticipated to increase from $8.2 billion in 2025 to $8.65 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.5%. The historical growth of this market can be attributed to an aging population, a rise in eye disease prevalence, advancements in ophthalmic diagnostics, the early adoption of drug therapy, and the proliferation of eye clinics.

The glaucoma market size is expected to witness substantial growth in the upcoming years. It is forecast to expand to $10.62 billion by 2030, achieving a compound annual growth rate (CAGR) of 5.3%. This projected expansion can be attributed to advancements in imaging technology, the development of surgical innovations, digital solutions for eye health monitoring, initiatives for early detection, and increasing investments in ophthalmology. Prominent trends throughout this period include the growing adoption of early diagnostic screening, increased utilization of combination drug therapies, the expansion of minimally invasive glaucoma surgery, broader availability of home-based eye monitoring, and enhanced patient awareness programs.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=32465716&type=smp&name=Glaucoma%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glaucoma Market Growth Drivers: What’s Behind The Acceleration?

The escalating occurrence of chronic eye conditions is anticipated to significantly advance the growth of the glaucoma market. These long-term disorders affect the eyes, frequently causing persistent vision impairment or discomfort and requiring continuous management or treatment. The increase in chronic eye conditions is largely attributed to aging populations, extended screen time, various lifestyle factors, and a higher prevalence of diseases such as diabetes and hypertension. Glaucoma treatment is crucial for these chronic eye conditions to effectively lower intraocular pressure, prevent further optic nerve damage, and preserve vision, as untreated glaucoma carries the risk of irreversible blindness. For instance, in December 2024, the National Health Service (NHS), a publicly funded healthcare system in the UK, reported that over 2 million people in the UK were living with sight loss in 2024. Furthermore, this number is projected to increase by 27%, reaching approximately 2.8 million by 2035. Thus, the increasing prevalence of chronic eye conditions is a primary driver for the glaucoma market.

Glaucoma Market Segment Performance And Emerging Opportunities

The glaucoma market covered in this report is segmented –

1) By Disease Type: Open Angle Glaucoma, Angle Closure Glaucoma, Other Disease Types

2) By Diagnosis: Tonometry, Ophthalmoscopy, Perimetry, Gonioscopy

3) By Drug Class: Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Combination Drugs, Other Drug Classes

4) By Administration: Oral, Injections, Intravitreal, Other Administrations

5) By End-User: Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers

Subsegments:

1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG), Secondary Open Angle Glaucoma

2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma, Secondary Angle Closure Glaucoma

3) By Other Disease Types: Normal-Tension Glaucoma, Pigmentary Glaucoma, Pseudoexfoliative Glaucoma, Congenital Glaucoma

Glaucoma Market Trends Redefining Industry Growth

Leading companies within the glaucoma market are concentrating on developing innovative treatments, such as Rho-kinase (ROCK) inhibitors. These therapies offer a dual mechanism of action, which effectively lowers intraocular pressure by both enhancing the outflow of aqueous humor and relaxing trabecular meshwork cells, thereby proving effective in glaucoma management. Rho-kinase (ROCK) inhibitors represent a drug class designed to target and inhibit the activity of Rho-kinase enzymes, which play a role in regulating cell contraction and are used to treat glaucoma by reducing intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., an eye care products company based in Japan, introduced Roclanda into the UK market. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, and it is effective at lowering intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is prescribed for adult patients diagnosed with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with a single therapy involving a prostaglandin or netarsudil. Roclanda’s launch in Europe signifies the first new category of glaucoma medication in 25 years, representing a significant advancement in treatment. Through its combination of netarsudil and latanoprost, Roclanda acts synergistically to boost outflow via both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive strategy for managing elevated IOP.

Glaucoma Market Key Players: Which Companies Lead Industry Competition?

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG

View The Full Glaucoma Market Report:

https://thebusinessresearchcompany.com/report/glaucoma-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Nov_PR

Glaucoma Market Global Footprint: Which Region Leads The Market?

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model